Sanofi Loses Bid to Revive Lantus Solostar Insulin-Pen Patents

Sanofi lost its appeals court bid to revive patents on its blockbuster Lantus SoloStar insulin injection pen in a victory for drugmaker Viatris Inc.

A review board was correct to invalidate five patents for a pen-type injection device that allows a user to set and administer a dose of medication, the U.S. Court of Appeals for the Federal Circuit said in a series of three rulings Wednesday.

Sanofi had been counting on the patents to help it block rival versions of the insulin treatment. Lantus generated global sales of 1.9 billion euros ($2.2 billion) in the first nine months of ...